Mi­rati gaug­ing sale in­ter­est of Big Phar­mas — re­port

Mi­rati Ther­a­peu­tics, mak­er of the ex­per­i­men­tal can­cer drug ada­gra­sib, is piquing the in­ter­est of Big Phar­mas, ac­cord­ing to a re­port from Bloomberg.

On Tues­day, the biotech’s stock $MRTX rose by al­most 16%, jump­ing from just un­der $75 to over $86. Af­ter Wednes­day’s open­ing bell, Mi­rati’s stock con­tin­ued to climb near­ly $3 apiece. But that still leaves it down 43% from the be­gin­ning of this year, a re­flec­tion of the biotech mar­ket as a whole.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER